Eli Lilly and Company (NYSE:LLY) Earnings Preview and Stock Analysis

• Cantor Fitzgerald reaffirms its "Overweight" rating for Eli Lilly (NYSE:LLY), increasing its price target from $825 to $925.
• Eli Lilly partners with HealthTap to enhance its digital healthcare platform, LillyDirect, focusing on virtual diabetes management services.
• The addition of Peter Marks, a former top vaccine regulator, to Eli Lilly's team is expected to bolster the company's pharmaceutical innovations.

Eli Lilly (NYSE:LLY) is a leading pharmaceutical company known for its innovative treatments and therapies. On October 9, 2025, Cantor Fitzgerald reaffirmed its "Overweight" rating for LLY, with the stock trading at $845.72. The firm also increased its price target from $825 to $925, indicating confidence in the company's future performance.

Eli Lilly's recent partnership with HealthTap, a telehealth company, is a strategic move to enhance its digital healthcare platform, LillyDirect. This collaboration focuses on providing virtual diabetes management services, which aligns with Lilly's commitment to improving patient care. The integration of HealthTap's services is expected to strengthen Lilly's position in the digital health space.

The addition of Peter Marks, former top vaccine regulator at the U.S. Food and Drug Administration, to Eli Lilly's team is a significant development. As reported by STAT News, Marks' expertise in vaccine regulation is anticipated to be a valuable asset for the company. His experience will likely support Lilly's efforts in advancing its pharmaceutical innovations.

LLY's stock price reflects a modest increase of $2.09, or approximately 0.25%, reaching $845.72. The stock has fluctuated between $845 and $856 today, with a 52-week high of $937 and a low of $623.78. Eli Lilly's market capitalization is approximately $760.6 billion, highlighting its substantial presence in the pharmaceutical industry.

The trading volume for LLY on the NYSE is 1,710,585 shares, indicating active investor interest. Cantor Fitzgerald's updated price target and the company's strategic initiatives, such as the HealthTap partnership and the addition of Peter Marks, suggest a positive outlook for Eli Lilly's future growth and market performance.

• Daiwa sets a price target of $700 for Eli Lilly (NYSE:LLY) but downgrades it to Neutral due to disappointing phase 3 study results of orforglipron.
• Eli Lilly's weight loss drug, Zepbound, drives significant revenue, but market preference is shifting towards oral pills over injectables.
• LLY's stock price reflects a 2.45% increase, with a market capitalization of approximately $663.68 billion.

Eli Lilly (NYSE:LLY) is a major player in the healthcare industry, known for its innovative pharmaceutical products. On August 17, 2025, Narumi Nakagiri from Daiwa set a price target of $700 for LLY. At that time, the stock was trading at $701.23, slightly above the target by 0.18%. Despite this, Daiwa downgraded the stock to Neutral from Outperform, as reported by TheFly.

Eli Lilly has faced challenges recently, particularly with its investigational oral GLP-1 candidate, orforglipron. The phase 3 study results were disappointing, impacting the company's stock performance. This setback opens a potential $10 billion opportunity for competitors like Novo Nordisk, Eli Lilly's main rival in the GLP-1 medicines market.

Eli Lilly's weight loss drug, Zepbound, has been a significant revenue driver, generating billions in quarterly sales. However, the market preference is shifting towards oral pills over injectable therapies like Zepbound and Novo Nordisk's Wegovy. Pills are easier and less costly to produce, store, and transport, which could alter market dynamics.

Currently, LLY's stock price is $701.23, reflecting a 2.45% increase or $16.80. The stock has traded between $685.80 and $706.79 today. Over the past year, LLY reached a high of $972.53 and a low of $623.78. The company's market capitalization is approximately $663.68 billion, with a trading volume of 8,116,656 shares on the NYSE.

Eli Lilly (NYSE:LLY) saw its stock fall over 14% on Thursday after its experimental weight-loss pill showed lower efficacy compared to Novo Nordisk’s (NYSE:NVO) rival treatment, despite reporting strong second-quarter results.

A late-stage study found that Lilly’s once-daily pill, orforglipron, led to a 12.4% reduction in body weight over 72 weeks, compared to 0.9% for placebo participants. Analysts had anticipated results closer to the 14.9% weight loss shown by Novo’s Wegovy in a 2021 trial.

The trial results follow a June study from Novo Nordisk showing its experimental drug CagriSema achieved nearly 23% weight loss in obese or overweight adults.

Despite the trial disappointment, Lilly posted strong financials. Q2 revenue surged 38% year-over-year to $15.56 billion, led by better-than-expected sales of Zepbound, which brought in $3.38 billion.

Adjusted earnings per share climbed to $6.31 from $3.92 a year earlier. Revenue exceeded consensus estimates of $14.7 billion.

Lilly raised its full-year 2025 revenue guidance to $60 billion to $62 billion, up $1.5 billion at the midpoint. Adjusted EPS was also revised upward to $21.75 to $23.

Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company based in Indianapolis, known for its innovative treatments and therapies. The company is set to release its first-quarter earnings on May 1, 2025. Guggenheim has maintained a "Buy" rating for LLY, with the stock price at $898.95, as highlighted by Benzinga.

Analysts expect Eli Lilly to report earnings of $3.46 per share, a notable increase from $2.58 per share in the same period last year. The anticipated revenue is $12.72 billion, up from $8.77 billion a year earlier. This growth reflects the company's strong performance and strategic advancements in the pharmaceutical sector.

Eli Lilly's recent topline Phase 3 results from the ACHIEVE-1 trial of orforglipron have positively impacted its stock, which rose by 1.6% to $898.95. The trial showed promising results for type 2 diabetes patients, positioning orforglipron as a potential leader in oral obesity treatments, comparable to existing therapies like oral and injectable semaglutide.

The stock's technical indicators show a bullish trend, trading above key moving averages. LLY is above its five-day, 20-day, and 50-day exponential moving averages, as well as its eight-day, 20-day, and 50-day simple moving averages. It also remains above its 200-day SMA of $844.59, a positive sign for long-term investors.

Eli Lilly's stock has performed well, rising 14.35% over the past year and 14.79% year-to-date. The current stock price of $898.95 reflects a 1.55% increase, with a trading range between $882.12 and $902.50. The company's market capitalization is approximately $852.19 billion, with a trading volume of 3,154,448 shares on the NYSE.

Eli Lilly and Company (NYSE:LLY) is a prominent player in the pharmaceutical industry, known for its innovative treatments in areas like diabetes and oncology. The company has a strong market presence, competing with other giants like Pfizer and Merck. On January 17, 2025, Leerink Partners reiterated its "Outperform" rating for LLY, with the stock trading at $740.15.

Eli Lilly has experienced significant growth since late 2020, becoming the world's largest healthcare entity with a market capitalization peaking at over $860 billion. However, recent challenges have led to a decline in stock performance. The stock price currently stands at $740.35, reflecting a 2.28% decrease, with a trading range today between $738.13 and $755.28.

The downturn in Eli Lilly's stock is partly due to a sell-off following the company's decision to cut its 2024 revenue guidance. This decision was influenced by lower-than-expected demand for its obesity and diabetes medications. The company's market capitalization now stands at approximately $702.83 billion, a notable decrease from its peak.

Interestingly, political developments could impact Eli Lilly's stock positively. Former President Donald Trump's campaign pledge to impose substantial tariffs on imported products might influence market dynamics. Such measures could potentially make Eli Lilly's stock an attractive buy, as highlighted by the potential for increased domestic market competitiveness.

Despite recent challenges, Eli Lilly's stock has shown resilience. Over the past year, it reached a high of $972.53 and a low of $614.82. With a trading volume of 2,038,469 shares on the NYSE, the stock remains actively traded, reflecting continued investor interest in the company's long-term prospects.

Eli Lilly and Company (NYSE:LLY) is a prominent player in the pharmaceutical industry, known for its innovative treatments in areas like diabetes and oncology. The company has a strong market presence, competing with other giants like Pfizer and Merck. On January 17, 2025, Leerink Partners reiterated its "Outperform" rating for LLY, with the stock trading at $740.15.

Eli Lilly has experienced significant growth since late 2020, becoming the world's largest healthcare entity with a market capitalization peaking at over $860 billion. However, recent challenges have led to a decline in stock performance. The stock price currently stands at $740.35, reflecting a 2.28% decrease, with a trading range today between $738.13 and $755.28.

The downturn in Eli Lilly's stock is partly due to a sell-off following the company's decision to cut its 2024 revenue guidance. This decision was influenced by lower-than-expected demand for its obesity and diabetes medications. The company's market capitalization now stands at approximately $702.83 billion, a notable decrease from its peak.

Interestingly, political developments could impact Eli Lilly's stock positively. Former President Donald Trump's campaign pledge to impose substantial tariffs on imported products might influence market dynamics. Such measures could potentially make Eli Lilly's stock an attractive buy, as highlighted by the potential for increased domestic market competitiveness.

Despite recent challenges, Eli Lilly's stock has shown resilience. Over the past year, it reached a high of $972.53 and a low of $614.82. With a trading volume of 2,038,469 shares on the NYSE, the stock remains actively traded, reflecting continued investor interest in the company's long-term prospects.